Nicotinamide Riboside for Chemotherapy-Induced Peripheral Neuropathy
Trial Summary
What is the purpose of this trial?
The purpose of this randomized, double-blind, placebo-controlled, parallel group phase II trial is to determine whether nicotinamide riboside (NIAGEN®, NR) can ameliorate persistent peripheral neuropathy in cancer survivors who have completed chemotherapy with taxane or platinum-complex compounds between 1 and 12 months earlier.
Research Team
Mohammed Milhem, MBBS
Principal Investigator
University of Iowa
Donna Hammond, Ph.D.
Principal Investigator
University of Iowa
Michael Shy, M.D.
Principal Investigator
University of Iowa
Eligibility Criteria
This trial is for cancer survivors aged 18-85 who finished chemotherapy with taxane or platinum compounds between 1 month and a year ago, have no visible disease now, can take oral medication, and are experiencing persistent peripheral neuropathy. Women must meet certain reproductive criteria; men must avoid fathering children during the study.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either placebo or NIAGEN capsules daily for 84 days, with regular assessments and biomarker measurements
Follow-up
Participants are monitored for safety and effectiveness after treatment, with all measures conducted again to assess persistence of alleviation
Treatment Details
Interventions
- Nicotinamide Riboside
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Iowa
Lead Sponsor
Donna Hammond, PhD
Lead Sponsor